Profile data is unavailable for this security.
About the company
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
- Revenue in USD (TTM)0.00
- Net income in USD-102.04m
- Incorporated2010
- Employees57.00
- LocationMind Medicine (MindMed) IncOne World Trade Center, Suite 8500NEW YORK 10007United StatesUSA
- Phone+1 (212) 220-6633
- Fax+1 (888) 848-3972
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics Inc | 20.65m | -192.65m | 439.20m | 255.00 | -- | 0.8036 | -- | 21.27 | -2.59 | -2.59 | 0.275 | 6.46 | 0.032 | -- | 8.05 | 80,972.55 | -29.87 | -- | -31.67 | -- | -- | -- | -933.03 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| C4 Therapeutics Inc | 29.38m | -107.87m | 440.29m | 145.00 | -- | 1.77 | -- | 14.99 | -1.90 | -1.90 | 0.4944 | 3.59 | 0.0777 | -- | 26.77 | 202,606.90 | -28.53 | -25.91 | -33.00 | -29.45 | -- | -- | -367.17 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Taysha Gene Therapies Inc | 12.87m | -114.34m | 440.63m | 52.00 | -- | 3.98 | -- | 34.23 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 440.71m | 181.00 | -- | 1.11 | -- | 35.78 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Larimar Therapeutics Inc | 0.00 | -58.34m | 451.11m | 42.00 | -- | 2.13 | -- | -- | -1.11 | -1.11 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -33.44 | -42.22 | -36.41 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| SAGE Therapeutics Inc | 97.24m | -445.67m | 457.88m | 487.00 | -- | 0.7272 | -- | 4.71 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Prime Medicine Inc | 591.00k | -217.44m | 459.72m | 234.00 | -- | 2.34 | -- | 777.86 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Aura Biosciences Inc | 0.00 | -80.69m | 474.73m | 88.00 | -- | 2.48 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 478.25m | 40.00 | -- | 3.69 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -102.04m | 480.28m | 57.00 | -- | 2.13 | -- | -- | -2.26 | -2.26 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -49.75 | -- | -61.24 | -- | -- | -- | -- | -- | -- | -- | 0.1072 | -- | -- | -- | -68.55 | -- | -- | -- |
| Absci Corp | 3.25m | -92.26m | 490.56m | 155.00 | -- | 2.21 | -- | 150.94 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -139.21m | 495.81m | 186.00 | -- | 2.19 | -- | -- | -2.30 | -2.30 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -57.01 | -40.85 | -61.38 | -44.48 | -- | -- | -- | -- | -- | -52.52 | 0.1151 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Contineum Therapeutics Inc | -100.00bn | -100.00bn | 510.35m | 31.00 | -- | 2.35 | -- | -- | -- | -- | -- | 8.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| OmniAB Inc | 21.71m | -62.38m | 522.28m | 106.00 | -- | 1.78 | -- | 24.05 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Mind Medicine (MindMed) Inc's reporting currency: US Dollar USD
39.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Commodore Capital LPas of 30 Jun 2024 | 7.15m | 8.78% |
| Deep Track Capital LPas of 30 Jun 2024 | 6.10m | 7.50% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.98m | 6.12% |
| Driehaus Capital Management LLCas of 30 Jun 2024 | 2.54m | 3.12% |
| Marshall Wace LLPas of 30 Jun 2024 | 2.16m | 2.66% |
| Octagon Capital Advisors LPas of 30 Jun 2024 | 2.15m | 2.65% |
| Blackstone Alternative Asset Management LPas of 30 Jun 2024 | 1.90m | 2.33% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.81m | 2.22% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.55m | 1.91% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.51m | 1.86% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
